文献速递耳科与耳神经

全球胆脂瘤疾病负担:系统评价与Meta分析

The Global Burden of Cholesteatoma: A Systematic Review and Meta-analysis.
PubMed 文献 · Otolaryngol Head Neck Surg · 2025-10-28

OBJECTIVE: This systematic review and meta-analysis sought to estimate the global and World Health Organization (WHO) regional prevalence and burden of cholesteatoma.…

要点

  • 全球胆脂瘤患病率约为4.02/1000人。
  • WHO非洲区域患病率最高,为7.32/1000人。
  • 胆脂瘤患者听力损失患病率为75.68/100例。

核心结论

  • 全球胆脂瘤患病率约为4.02/1000人,存在区域差异。
  • 胆脂瘤患者听力损失患病率约为75.68/100例。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、APA PsycINFO、Cochrane Library、Embase和WHO ICTRP从2010年至2025年的文献。

主要发现

  • 全球胆脂瘤合并患病率为4.02/1000人(95%CI 1.79-7.10)。
  • WHO西太平洋区域患病率为5.73/1000人(95%CI 1.00-13.87)。
  • WHO欧洲区域患病率为2.32/1000人(95%CI 2.23-2.42)。
  • WHO东南亚区域患病率为3.30/1000人(95%CI 2.65-4.11)。
  • WHO美洲区域患病率为0.06/1000人(95%CI 0.00-0.00),非洲区域为7.32/1000人(95%CI 2.77-13.96)。

关键数值与推荐

  • 全球胆脂瘤患病率:4.02/1000人(95%CI 1.79-7.10)。
  • 胆脂瘤患者听力损失患病率:75.68/100例(95%CI 59.02-89.24)。

临床怎么用

  • 提示临床医生关注胆脂瘤的区域流行病学差异,在患病率较高地区加强筛查与早期诊断。
  • 对胆脂瘤患者应常规评估听力损失,因其患病率较高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This systematic review and meta-analysis sought to estimate the global and World Health Organization (WHO) regional prevalence and burden of cholesteatoma. DATA SOURCES: PubMed, APA PsycINFO, the Cochrane Library, Embase, and WHO International Clinical Trials Registry Platform (ICTRP) from 2010 to 2025. REVIEW METHODS: Teams of independent reviewers assessed each study for inclusion. Studies reporting primary data on cholesteatoma prevalence, recurrence, or its impact were included. The primary outcome was the global prevalence, whereas secondary outcomes were regional prevalence and recidivism rates, treatment, and complications. A random-effects meta-analysis was used to pool data, and study quality and publication bias were assessed. This study was registered with PROSPERO (CRD42024533132). RESULTS: Forty-six eligible studies were included in the meta-analysis. The pooled global prevalence of cholesteatoma was estimated at 4.02 per 1000 persons (95% CI 1.79-7.10). By the WHO regions, the pooled prevalence of cholesteatoma in the Western Pacific Region, European Region, South East Asian Region, Region of the Americas, and African Region was estimated at 5.73 per 1000 persons (95% CI 1.00-13.87), 2.32 per 1000 persons (95% CI 2.23-2.42), 3.30 per 1000 persons (95% CI 2.65-4.11), 0.06 per 1000 persons (95% CI 0.00-0.00), and 7.32 per 1000 persons (95% CI 2.77-13.96), respectively. The prevalence of hearing loss in cholesteatoma was estimated at 75.68 per 100 cases (95% CI 59.02-89.24). CONCLUSION: This meta-analysis is the first to systematically quantify global and regional cholesteatoma prevalence, complications, and treatment approaches, highlighting regional disparities and informing public health strategies and policy globally.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Melariri H, Balakrishna Y, Mukhtar A, et al. The Global Burden of Cholesteatoma: A Systematic Review and Meta-analysis. Otolaryngol Head Neck Surg. 2025. PMID: 41147202. doi:10.1002/ohn.70057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。